COMPANY
Novaliq
Timeline
- Trial start Phase 2: Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis source ↗
- Trial start Phase 4: A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine source ↗
- Trial start Phase 3: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004 source ↗
- Trial start Phase 3: ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) source ↗
- Trial start —: Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye source ↗
- Trial start Phase 2: Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) source ↗
- Trial start Phase 2/Phase 3: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) source ↗
- Trial start Not phased (device or behavioral study): Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease source ↗
- Trial start Phase 2: CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED) source ↗
- Trial start —: NovaTears® Eye Drops Observational Study NT-003 source ↗
- Trial start —: NovaTears® Eye Drops Observational Study NT-002 source ↗
- Trial start 1: CyclASol® Phase 1 Study source ↗
- Trial start —: NovaTears® Eye Drops Observational Study source ↗
Upcoming milestones
- 2026-10 (ESTIMATED) · Phase 2 · Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis · NCT07285070
Clinical trials (lead sponsor) 13
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06329661 | A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine | Phase 4 | Completed | Apr 22, 2024 | Jul 30, 2025 (actual) |
| NCT07285070 | Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis | Phase 2 | Recruiting | Mar 16, 2026 | 2026-10 (estimated) |
| NCT04523142 | CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004 | Phase 3 | Completed | Jan 4, 2021 | Apr 30, 2022 (actual) |
| NCT04523129 | ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) | Phase 3 | Completed | Dec 5, 2020 | Sep 3, 2021 (actual) |
| NCT03292809 | CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) | Phase 2/Phase 3 | Completed | Oct 19, 2017 | May 22, 2018 (actual) |
| NCT03333057 | Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) | Phase 2 | Completed | Jan 3, 2018 | May 18, 2018 (actual) |
| NCT04521465 | Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye | Not listed | Completed | Nov 9, 2020 | Feb 17, 2021 (actual) |
| NCT02617667 | CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED) | Phase 2 | Completed | 2016-01 | 2016-07 (actual) |
| NCT03048526 | Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease | Not phased (device or behavioral study) | Completed | Dec 15, 2016 | Apr 18, 2017 (actual) |
| NCT02356328 | NovaTears® Eye Drops Observational Study NT-003 | Not listed | Completed | 2015-01 | 2016-01 (actual) |
| NCT02356341 | NovaTears® Eye Drops Observational Study NT-002 | Not listed | Completed | 2015-01 | 2015-12 (actual) |
| NCT02111928 | NovaTears® Eye Drops Observational Study | Not listed | Completed | 2013-12 | 2014-05 (actual) |
| NCT02113293 | CyclASol® Phase 1 Study | 1 | Completed | 2014-03 | 2014-05 (actual) |